ANI Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 642
- Market Cap
- $1.3B
- Introduction
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.
ANI Pharmaceuticals launches generic Ketoconazole Shampoo
ANI Pharmaceuticals launches Ketoconazole Shampoo, 2%, following FDA approval, aiming to address unmet medical needs and expand its generics business. The company also completed the acquisition of Alimera Sciences, broadening its ophthalmology portfolio, and reported a robust Q2 2024 with a revenue increase of 18% to $138 million, driven by its rare disease asset and generics business. ANI Pharmaceuticals' market capitalization is $1.12 billion, with a 34.27% revenue growth over the last twelve months and a gross profit margin of 61.34%.
ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2%
ANI Pharmaceuticals launched Ketoconazole Shampoo, 2% after FDA approval, aiming to address patient needs with limited competition products.
ANI Pharmaceuticals announces FDA approval, launch of Ketoconazole Shampoo, 2%
ANI Pharmaceuticals launched Ketoconazole Shampoo, 2% after FDA approval, a generic version of Nizoral with U.S. annual sales of $69.2M.
ANI Pharmaceuticals Announces the FDA Approval and Launch
ANI Pharmaceuticals launched Ketoconazole Shampoo, 2% after FDA approval, aiming to address patient needs with another limited competition product. U.S. annual sales for the shampoo are approximately $69.2 million.
Avenacy Announces Launch of Metoclopramide Injection, USP in the U.S. Market
Avenacy launched Metoclopramide Injection, USP in the U.S., a therapeutic generic equivalent for Reglan®, indicated for diabetic gastroparesis, nausea/vomiting prevention, small bowel intubation, and radiological examination. The product is available in 10 mg/2 mL single-dose vials, featuring differentiated packaging for patient safety.
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
ANI Pharmaceuticals initiated closing logistics for the acquisition of Alimera Sciences, with expected completion pending customary closing conditions.
ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan
ANI Pharmaceuticals launched Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, 6.25 mg/15 mg per 5 mL, its 14th new product in 2024, contributing to strong growth in its Generics business. The launch is strategic, timed with the upcoming cough and cold season, and aligns with ANI's expansion strategy, targeting $42.6 million in annual U.S. sales.
ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
ANI Pharmaceuticals updates on Alimera Sciences acquisition, noting ongoing good faith discussions to resolve closing conditions.
© Copyright 2025. All Rights Reserved by MedPath